KCNMA1 and bacterial pneumonia: These effects appear to be mediated by reducing the secretion of the neutrophil/macrophage chemoattractants CCL-225 and MIP-1α26 and upregulating antioxidant responses, suggesting BK channels as potential targets for anti-inflammatory drug design against bacterial pneumonia.